Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial

TY - JOUR

T1 - Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome

T2 - a double-blind controlled trial

AU - Belch, Jill J. F.

AU - Drury, John K.

AU - Capell, Hilary

AU - Forbes, Charles D.

AU - Newman, Peter

AU - McKenzie, Fiona

AU - Leiberman, Paul

AU - Prentice, Colin R. M.

PY - 1983

Y1 - 1983

N2 - Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.

AB - Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.

U2 - 10.1016/S0140-6736(83)91624-0

DO - 10.1016/S0140-6736(83)91624-0

M3 - Article

C2 - 6130329

SN - 0140-6736

VL - 1

SP - 313

EP - 315

JO - Lancet

JF - Lancet

IS - 8320

ER -